A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
NCT ID: NCT00277498
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
528 participants
INTERVENTIONAL
2005-12-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
NCT00159653
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
NCT00140049
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
NCT00219596
Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
NCT01191008
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
NCT00230763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xalacom
Xalatan
Timolol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Flagstaff, Arizona, United States
Pfizer Investigational Site
Artesia, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Colorado Springs, Colorado, United States
Pfizer Investigational Site
Gainesville, Florida, United States
Pfizer Investigational Site
Lecanto, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Panama City, Florida, United States
Pfizer Investigational Site
Idaho Falls, Idaho, United States
Pfizer Investigational Site
Bourbonnais, Illinois, United States
Pfizer Investigational Site
Calumet City, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Madison, Indiana, United States
Pfizer Investigational Site
New Albany, Indiana, United States
Pfizer Investigational Site
Newburgh, Indiana, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Bangor, Maine, United States
Pfizer Investigational Site
Reading, Massachusetts, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Stillwater, Minnesota, United States
Pfizer Investigational Site
Creve Coeur, Missouri, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Warrensburg, Missouri, United States
Pfizer Investigational Site
Washington, Missouri, United States
Pfizer Investigational Site
Piscataway, New Jersey, United States
Pfizer Investigational Site
Princeton, New Jersey, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Greensboro, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Roseburg, Oregon, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Reading, Pennsylvania, United States
Pfizer Investigational Site
Wyomissing, Pennsylvania, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Maryville, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
El Paso, Texas, United States
Pfizer Investigational Site
El Paso, Texas, United States
Pfizer Investigational Site
Fort Worth, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Fredericksburg, Virginia, United States
Pfizer Investigational Site
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS; United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010 Feb;128(2):165-72. doi: 10.1001/archophthalmol.2009.384.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6641044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.